Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • Rights Issue 2022
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
      • Management stories
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Rights Issue 2022
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

Regulatory Releases
  • Press Releases
  • All releases
2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Regulatory
June 13, 2022

Vivesto and CEO Francois Martelet have agreed on ending the employment relationship

Regulatory
May 25, 2022

Report from Annual General Meeting in Vivesto AB

Regulatory
May 25, 2022

Interim report for the period January 1, 2022 – March 31, 2022

Regulatory
April 29, 2022

New number of shares and votes in Vivesto

Regulatory
April 28, 2022

Correction: Vivesto publishes Annual Report for 2021

Regulatory
April 28, 2022

Vivesto publishes Annual Report for 2021

Regulatory
April 25, 2022

Notice of Annual General Meeting in Vivesto AB

Regulatory
April 19, 2022

The Nomination Committee of Vivesto proposes election of new Board members and new Chairman of the Board

Regulatory
March 31, 2022

New number of shares and votes in Vivesto

Regulatory
March 25, 2022

FINAL RESULT OF OASMIA’S RIGHTS ISSUE

Regulatory
March 24, 2022

PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE

Regulatory
March 3, 2022

Oasmia announces CFO Fredrik Järrsten to step down later this year

Regulatory
March 3, 2022

OASMIA PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE

Regulatory
February 24, 2022

Year-end report January 1, 2021 – December 31, 2021

Regulatory
February 21, 2022

Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB

Regulatory
January 19, 2022

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB

Regulatory
January 19, 2022

OASMIA RESOLVES ON A FULLY SECURED RIGHTS ISSUE OF APPROXIMATELY SEK 151 MILLION

Investor contact

Cord Communications
IR@vivesto.com
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com